STOCK TITAN

Brainsway Ltd. American Depositary Shares - BWAY STOCK NEWS

Welcome to our dedicated page for Brainsway Ltd. American Depositary Shares news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. American Depositary Shares stock.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) is a leading global neurostimulation company headquartered in Jerusalem and the U.S., specializing in advanced noninvasive treatments for mental health disorders. With its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology, BrainsWay has revolutionized the field of brain disorder treatment, offering hope to millions of patients worldwide.

The company's innovative solutions target major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction. BrainsWay's Deep TMS is FDA-cleared for its efficacy in treating these conditions. Clinical trials are ongoing for additional indications, including various psychiatric, neurological, and addiction disorders, aiming to expand the reach of this cutting-edge technology.

BrainsWay's treatments are non-invasive, safe, and convenient, typically requiring only brief daily sessions over a few weeks. This approach has already treated over 10,000 patients, delivering significant improvements without long-term side effects. The company leases and sells its Deep TMS systems, generating revenue while expanding its global footprint.

Recent collaborations, such as the partnership with Katie’s Way for providing mental health care to U.S. servicemembers, veterans, and their families, highlight BrainsWay's commitment to addressing critical mental health needs. This partnership underscores the transformative impact of Deep TMS technology in treating depression, particularly within the military community, where mental health issues are on the rise.

BrainsWay has also achieved significant milestones, such as being the first TMS company to receive three FDA-clearances for different indications, backed by pivotal clinical studies. The company's financial health is robust, with a reported 37% year-over-year revenue growth in the first quarter of 2024 and positive net income for consecutive quarters.

Looking ahead, BrainsWay continues to pursue innovations, including a clinical trial comparing accelerated Deep TMS protocols with standard treatments. This trial aims to enhance the convenience and appeal of Deep TMS, potentially broadening its market reach.

For more information about BrainsWay and its latest news, visit the company's website or follow their updates on StockTitan.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
none
-
Rhea-AI Summary
BrainsWay to report Q1 2023 financial results and operational highlights on May 17, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) announced a publication revealing impressive results from a post-marketing study on its Deep TMS™ treatment for depression. The study, featured in Psychiatry Research, involved 1,351 patients and demonstrated an 82% response rate and a 65% remission rate among those receiving 30 or more treatments. This data underscores the effectiveness of Deep TMS for patients who have previously failed over seven medication trials. With almost 75% of patients achieving remission based on the Hamilton Depression Rating Scale, the findings reinforce BrainsWay's commitment to advancing neurostimulation therapies for mental health disorders amidst a growing global mental health crisis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) announced its fourth quarter and full-year 2022 results, revealing a 29% revenue decline to $6.0 million compared to Q4 2021. For the full year, revenues decreased 8% to $27.2 million, while the net loss widened to $13.3 million.

Despite these challenges, the installed base of Deep TMS™ systems grew 17% to 884 units. The company holds $47.9 million in cash as of year-end 2022. New CEO Hadar Levy aims for revenue growth and breakeven operating income by Q4 2023, bolstered by improved insurance coverage for Deep TMS treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) announced plans to report its Q4 and full-year 2022 financial results on March 15, 2023, prior to U.S. market opening. The company will host a conference call at 8:30 AM ET to discuss these results and provide business updates. BrainsWay specializes in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its Deep TMS technology, which has received FDA clearance for multiple indications including major depressive disorder and obsessive-compulsive disorder. This announcement aims to inform stakeholders and enhance transparency regarding its operational performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences earnings
-
Rhea-AI Summary

Burlington, Mass. and Jerusalem, Feb. 23, 2023 - BrainsWay (NASDAQ: BWAY) announced that Dr. Colleen Hanlon received the 2023 International Brain Stimulation Early Career Award at the 5th International Brain Stimulation Conference in Lisbon, Portugal. This recognition highlights her significant contributions to brain stimulation and neuroscience. Dr. Hanlon, who previously served at Wake Forest University, has secured over $12 million in NIH funding and has authored a consensus paper on noninvasive neuromodulation in addiction. BrainsWay continues to lead in noninvasive neurostimulation treatments for mental health, with FDA-approved indications and ongoing clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
-
Rhea-AI Summary

BrainsWay Ltd. has appointed Hadar Levy as the new Chief Executive Officer, succeeding Christopher R. von Jako, who stepped down to pursue other opportunities. Levy, who has been with the company since 2014, served previously as Chief Financial Officer and COO, bringing extensive operational and financial expertise. The transition aims to leverage Levy's experience to capitalize on growth opportunities in the noninvasive neurostimulation market. BrainsWay is recognized for its innovative Deep TMS technology, targeting mental health disorders, including major depression, OCD, and smoking addiction, with FDA-cleared indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
management
Rhea-AI Summary

BrainsWay Ltd. (NASDAQ & TASE: BWAY) has announced a significant leadership change, with Ami Boehm appointed as Chairman of the Board, succeeding co-founder David Zacut, M.D., who will now serve as a Director. Zacut co-founded the company in 2003 and played a crucial role in its development into a leader in noninvasive neurostimulation treatments for mental health disorders. Boehm, a seasoned professional in capital markets, brings extensive experience, having notably served as a partner at FIMI Opportunity Funds. This transition is expected to enhance shareholder value as BrainsWay pursues growth opportunities in its sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
management

FAQ

What is the current stock price of Brainsway Ltd. American Depositary Shares (BWAY)?

The current stock price of Brainsway Ltd. American Depositary Shares (BWAY) is $9.24 as of December 20, 2024.

What is the market cap of Brainsway Ltd. American Depositary Shares (BWAY)?

The market cap of Brainsway Ltd. American Depositary Shares (BWAY) is approximately 169.9M.

What does BrainsWay Ltd. do?

BrainsWay Ltd. specializes in noninvasive neurostimulation treatments for mental health disorders using its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology.

What conditions does BrainsWay's technology treat?

BrainsWay's Deep TMS technology treats major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Additional indications are under clinical trials.

Is BrainsWay's treatment FDA-approved?

Yes, BrainsWay's Deep TMS technology has received FDA clearance for treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

How safe is BrainsWay's treatment?

BrainsWay's treatment is non-invasive, with no systemic or long-term side effects. It typically involves brief daily sessions over a few weeks.

What are BrainsWay's recent achievements?

BrainsWay recently reported a 37% year-over-year revenue growth and positive net income for consecutive quarters. They also expanded their collaboration with Katie’s Way to provide mental health treatment to military personnel.

Where is BrainsWay headquartered?

BrainsWay is headquartered in Jerusalem, Israel, and has offices in the U.S., specifically in Burlington, MA.

How many patients have been treated with BrainsWay's technology?

Over 10,000 patients have been treated with BrainsWay's Deep TMS technology worldwide.

What is Deep TMS?

Deep TMS stands for Deep Transcranial Magnetic Stimulation, a non-invasive neurostimulation method used to treat various mental health disorders.

What is the future outlook for BrainsWay?

BrainsWay is focused on expanding its clinical indications and improving its treatment protocols. They anticipate continued strong financial performance and are actively pursuing additional clinical trials for new applications of their technology.

How can I get more information about BrainsWay?

For the latest news and information about BrainsWay, visit their official website or follow updates on financial news platforms like StockTitan.

Brainsway Ltd. American Depositary Shares

Nasdaq:BWAY

BWAY Rankings

BWAY Stock Data

169.88M
16.17M
19.22%
0.23%
Medical Devices
Healthcare
Link
United States of America
Jerusalem